RBR-10k2w2c5
Active, not recruiting
Phase 3
Treatment of moderate to severe cases of the disease caused by the new coronavirus-2019 (COVID-19) with colchicine: a controlled open trial
Hospital das Clínicas de Ribeirão Preto0 sitesSeptember 28, 2021
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with COVID\-19; over 18 years old; at least 50 kg of body weight; moderate or severe form of COVID\-19; in need of treatment in a hospital environment; women between 18 and 50 years old should have a negative serum or urine test for beta human chorionic gonadotropin
Exclusion Criteria
- •Mild form of COVID\-19; allergy to colchicine; diagnosis of porphyria, myasthenia gravis or uncontrolled arrhythmia on admission; pregnancy or lactancy; use of cyclosporine, digoxin, amiodarone, verapamil, metoprolol or protease inhibitors; history of chronic liver disease with liver dysfunction; unable to understand the information contained in the consent form.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Test of the combination of prednisone and everolimus as a new approach in treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with newly diagnosed patientschronic Graft versus Host DiseaseMedDRA version: 14.1Level: LLTClassification code 10018799Term: GVHDSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.1Level: LLTClassification code 10063109Term: Transfusion associated GVHDSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.1Level: LLTClassification code 10068907Term: CGVHDSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 14.1Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>System Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2011-004847-35-DEniversity Medical Center Hamburg-Eppendorf60
Recruiting
Not Applicable
Clinical observation on the treatment of moderate female stress urinary incontinence with optimized formula of Qishi granules based on the theory of spleen kidney correlatioFemale stress urinary incontinenceITMCTR2024000008Xiyuan Hospital, China Academy of Chinese Medical Sciences
Not yet recruiting
Not Applicable
Should a patient with a clinically suspected scaphoid fracture be treated with a cast?clinical suspected scaphoid fracture. Klinische verdenking scaphoid fractuurNL-OMON20183Erasmus MC180
Completed
Not Applicable
sing two drugs in combination at the start of drug treatment for type 2 diabetes vs using a single drugISRCTN26805203Pakistan Institute of Medical Sciences285
Active, not recruiting
Phase 1
Orismilast for the treatment of moderate to severe ulcerative colitisCTIS2022-502763-37-02Hvidovre Hospital20